Voyager Therapeutics NASDAQ:VYGR Chief Financial Officer Nathan D. Jorgensen sold 4,668 shares of common stock on February 24, 2026, realizing proceeds of $17,598. The trades were completed at prices ranging from $3.61 to $3.86 per share.
The sale was carried out under a pre-arranged automatic sale instruction that Jorgensen adopted on May 9, 2025. The transaction was intended to cover tax withholding obligations stemming from the vesting of restricted stock units that occurred on February 21, 2026. A Form 4 filing notes that these sales were not discretionary on the part of Jorgensen.
After the sale, Jorgensen directly holds 151,416 shares of Voyager Therapeutics. The sale amount and the retained holdings are reported in the Form 4 submitted to regulators.
Market movement followed the transaction: Voyager Therapeutics' shares have rallied nearly 20% over the past week and are currently quoted at $4.18. The price range for the shares sold on February 24 remained below the current trading level.
In addition to the transaction details, InvestingPro analysis cited in public materials characterizes the stock as appearing undervalued at current levels and assigns a "FAIR" rating for the company’s financial health. The note references 11 additional ProTips and a broader Pro Research Report for investors seeking more in-depth analysis.
The filing and the InvestingPro snapshot together provide a factual record of the insider sale, the administrative nature of the transaction, and a recent third-party assessment of the stock’s valuation and financial condition. Where available, the Form 4 and the referenced InvestingPro materials supply the underlying documentation and commentary.
Where this sits in the market - The reported sale was executed to satisfy tax obligations tied to RSU vesting and was not a discretionary disposition, according to the Form 4. The subsequent share price uptick highlights short-term volatility but does not alter the recorded facts about the sale or about Jorgensen's remaining direct ownership.